In a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).
Feature|Articles|June 26, 2026
5 FDA decisions to watch for during 2H 2026
Author(s)Morgan Ebert, Executive Editor
Fact checked by: Benjamin P. Saylor
A preview of 5 pending FDA decisions for pediatric patients expected in the second half of 2026, spanning ADHD, psoriasis, a metabolic gene therapy, cardiomyopathy, and muscular dystrophy.
Advertisement
Advertisement
After a first half of 2026 that brought historic firsts for Menkes disease, arginase 1 deficiency, achondroplasia, plaque psoriasis, and the neurologic complications of Hunter syndrome, the FDA's pediatric pipeline shows no signs of slowing. The back half of the year carries a slate of priority review decisions spanning neurodevelopmental, cardiac, metabolic, and neuromuscular disease—several of which could establish the first pharmacologic options ever available to the children and adolescents they're intended to treat.
Related to this article
Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.
Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.
Find out the 4 FDA decisions to watch in November 2026 for pediatric care.
Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.
FDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.
A recap of the top pediatric clinical trial results and pipeline data readouts during October 2026.
A recap of the top FDA approvals, regulatory decisions, and pipeline updates affecting pediatric care during October 2026.
Advertisement
Advertisement